Invasive Aspergillosis And Candidiasis In Immunocompromised Patients Therapeutics
1. Noxafil patent expiration
Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5661151 | SCHERING | Tetrahydrofuran antifungals |
Jul, 2019
(6 years ago) | |
| US8263600 | SCHERING | Antifungal composition with enhanced bioavailability |
Apr, 2022
(3 years ago) | |
| US5703079 | SCHERING | Tetrahydrofuran antifungals |
Aug, 2014
(11 years ago) | |
| US6958337 | SCHERING | Crystalline antifungal polymorph |
Oct, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
NCE-1 date: 15 September, 2010
Market Authorisation Date: 15 September, 2006
Dosage: SUSPENSION
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
2. Noxafil patent expiration
Treatment: Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Prophylaxis of invasive aspergillus and candida...
NOXAFIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5661151 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Jul, 2019
(6 years ago) | |
| US5703079 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Aug, 2014
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358297 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(5 years from now) | |
| US9023790 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(5 years from now) | |
| US9750822 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(7 years from now) | |
| US10117951 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Dosage: SOLUTION; TABLET, DELAYED RELEASE
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents